Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2123

1.

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Health Technol Assess. 2001;5(1):1-137. Review.

2.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

3.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

4.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
5.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
6.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

7.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
8.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
9.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

10.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

11.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(1):CD001747. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747.

PMID:
11279727
13.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
14.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Review.

PMID:
22480339
15.

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H.

BMJ. 2005 Aug 6;331(7512):321-7. Review.

17.

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey R.

Cochrane Database Syst Rev. 2003;(3):CD001190. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001190.

PMID:
12917900
18.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
19.

Donepezil for vascular cognitive impairment.

Malouf R, Birks J.

Cochrane Database Syst Rev. 2004;(1):CD004395. Review.

PMID:
14974068
20.

Pharmacological interventions for cognitive decline in people with Down syndrome.

Livingstone N, Hanratty J, McShane R, Macdonald G.

Cochrane Database Syst Rev. 2015 Oct 29;(10):CD011546. doi: 10.1002/14651858.CD011546.pub2. Review.

PMID:
26513128

Supplemental Content

Support Center